Dx & Vx Co., Ltd. (KOSDAQ:180400)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,777.00
+27.00 (1.54%)
At close: Dec 5, 2025
3.43%
Market Cap 87.46B
Revenue (ttm) 29.47B
Net Income (ttm) -50.92B
Shares Out 49.22M
EPS (ttm) -1,034.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 254,150
Average Volume 184,865
Open 1,750.00
Previous Close 1,750.00
Day's Range 1,685.00 - 1,800.00
52-Week Range 1,309.00 - 2,890.00
Beta -0.07
RSI 39.56
Earnings Date Nov 14, 2025

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2001
Employees 88
Stock Exchange KOSDAQ
Ticker Symbol 180400
Full Company Profile

Financial Performance

In 2024, Dx & Vx's revenue was 33.95 billion, a decrease of -17.69% compared to the previous year's 41.24 billion. Losses were -47.03 billion, 71.1% more than in 2023.

Financial Statements

News

There is no news available yet.